Abstract
In COVID-19, hypertension and cardiovascular diseases have emerged as major risk factors for critical disease progression. Concurrently, the impact of the main anti-hypertensive therapies, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), on COVID-19 severity is controversially discussed. By combining clinical data, single-cell sequencing data of airway samples and in vitro experiments, we assessed the cellular and pathophysiological changes in COVID-19 driven by cardiovascular disease and its treatment options. Anti-hypertensive ACEi or ARB therapy, was not associated with an altered expression of SARS-CoV-2 entry receptor ACE2 in nasopharyngeal epithelial cells and thus presumably does not change susceptibility for SARS-CoV-2 infection. However, we observed a more critical progress in COVID-19 patients with hypertension associated with a distinct inflammatory predisposition of immune cells. While ACEi treatment was associated with dampened COVID-19-related hyperinflammation and intrinsic anti-viral responses, under ARB treatment enhanced epithelial-immune cell interactions were observed. Macrophages and neutrophils of COVID-19 patients with hypertension and cardiovascular comorbidities, in particular under ARB treatment, exhibited higher expression of CCL3, CCL4, and its receptor CCR1, which associated with critical COVID-19 progression. Overall, these results provide a potential explanation for the adverse COVID-19 course in patients with cardiovascular disease, i.e. an augmented immune response in critical cells for the disease course, and might suggest a beneficial effect of clinical ACEi treatment in hypertensive COVID-19 patients.
Competing Interest Statement
MSA has received personal fees from Servier outside the submitted work. All other authors declare no competing interest.
Funding Statement
This study was supported by the BIH COVID-19 research program, the European commission (ESPACE, 874719, Horizon 2020), the BMBF-funded de.NBI Cloud within the German Network for Bioinformatics Infrastructure (de.NBI; 031A537B, 031A533A, 031A538A, 031A533B,031A535A, 6031A537C, 031A534A, 031A532B), and the BMBF-funded Medical Informatics Initiative (HiGHmed, 01ZZ1802A -01ZZ1802Z). Illumina GmbH provided financial support via the allocation of reagents and sequencing flow cells. MSA has received research support from the German Cardiovascular Research Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the respective Institutional Review boards of the Charite-Universitaetsmedizin Berlin (EA2/066/20) or the University Hospital Leipzig (123/20-ek) and conducted in accordance with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to potential risk of de-identification of pseudonymized RNA sequencing data the raw data will be available under controlled access in the EGA repository, [will be added upon manuscript acceptance]. Count and metadata tables (patient-ID, sex, age, cell type, QC metrics per cell) can be found at FigShare: [will be added upon manuscript acceptance]. In addition, these data can be further visualized and analyzed in the Magellan COVID-19 data explorer at https://digital.bihealth.org [will be publicly available upon manuscript acceptance].
